Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Bullous dermatitis (2001): Christ EA+ (poster at meeting of the American Federation for Medical Research) Dermatitis Diaphoresis (2001): Hebert AA+, J Clin Psychiatry 62(suppl 14), 22 Edema (2002): Witters I+, Prenat Diagn 22(9), 834 Erythema multiforme (5%) Fixed eruption (1997): Chan HL+, JAmAcadDermatol36, 259 Furunculosis (
568 VALRUBICIN VALRUBICIN Trade name: Valstar (Celltech) Indications: Bladder carcinoma Category: Antibiotic, anthracycline Half-life: N/A Clinically important, potentially hazardous interactions with: None Reactions Skin Irritation (sic) (2%) (2003): Irons BK+, Ann Pharmacother 37(7–8), 1024 (2002): Biswas PN+, JHumHypertens16(11), 795 (2000): de la Serna Higuera C, Med Clin (Barc) (Spanish) 114, 599 (1998): Frye Cb+, Pharmacotherapy 18, 866 Bullous pemphigoid (2003): Femiano F, Minerva Stomatol 52(4), 187 Eczema (2006): Selden ST, Chesapeake VA (from Internet) (observation) Edema (>1%) (2000): Prat H, Rev Med Chil (Spanish) 128, 475 (1996): Corea L+, Clin Pharmacol Ther 60, 341 Facial edema (2002): Biswas PN+, JHumHypertens16(11), 795 Lupus erythematosus (2006): Sontheimer RD, Oklahoma City, OK (from Internet) (observation) Photosensitivity (1998): Frye Cb+, Pharmacotherapy (18) 866 Pruritus (>2%) Psoriasis (2005): Litt JZ, Beachwood, OH (personal case) (observation) Rash (sic) (>2%) Urticaria (2000): de la Serna Higuera C, Med Clin (Barc) (Spanish) 114, 599 Mucosal Aphthous stomatitis (1–10%) Xerostomia (>10%) Nails Nails – onychocryptosis Nails – pigmentation Other Cough (2002): Biswas PN+, JHumHypertens16(11), 795 (2000): Prat H, Rev Med Chil 128, 475 Death (2001): Briggs GG+, Ann Pharmacother 35(7), 859 Injection-site extravasation (
- Page 592 and 593: (1984): Stern RS+, JAMA 252, 1433 J
- Page 594 and 595: TACROLIMUS Synonym: FK506 Trade nam
- Page 596 and 597: (2005): Fumal I+, Dermatology 210(3
- Page 598 and 599: (2000): Ernst E+, Forsch Komplement
- Page 600 and 601: Reactions Skin Allergic reactions (
- Page 602 and 603: Reactions Skin Diaphoresis (>1%) Ed
- Page 604 and 605: Mucosal Oral ulceration (1987): Hig
- Page 606 and 607: TETRACYCLINE Trade names: Apo-Tetra
- Page 608 and 609: Xerosis (2002): Bariol C+, J Gastro
- Page 610 and 611: Eyes Conjunctivitis (allergic conta
- Page 612 and 613: Other Anaphylactoid reactions/Anaph
- Page 614 and 615: (2000): Chemnitz JM+, Med Klin (Ger
- Page 616 and 617: Note: Cutaneous side-effects of bet
- Page 618 and 619: Other Cough (0.8%) Fever (4.6%) Hep
- Page 620 and 621: TOLAZAMIDE* Trade names: Diabewas;
- Page 622 and 623: Reactions Skin Erythema (1.9%) Fung
- Page 624 and 625: TOSITUMOMAB & IODINE 131 Trade name
- Page 626 and 627: (2001): Vogel CL+, Oncology 61, 37
- Page 628 and 629: (1997): Gilchrest BA, JAmAcadDermat
- Page 630 and 631: Erythema (1999): Alexiou C+, Laryng
- Page 632 and 633: *Note: Trichlormethiazide is a sulf
- Page 634 and 635: TRIMETHOPRIM* Trade names: Abaprim;
- Page 636 and 637: Myalgia/Myositis/Myopathy/Myotoxici
- Page 638 and 639: Other Death (2002): Avarello TP+, N
- Page 640 and 641: (2001): Pechlaner C+, Blood Coagul
- Page 644 and 645: (1985): Schifter S+, Lancet 2, 499
- Page 646 and 647: Reactions Skin Allergic reactions (
- Page 648 and 649: VERAPAMIL Trade names: APO-Verap; A
- Page 650 and 651: Mucosal Gingival hyperplasia/hypert
- Page 652 and 653: (2001): Laack E+, Ann Oncol 12(12),
- Page 654 and 655: Fixed eruption (
- Page 656 and 657: (1986): Sjoberg A+, Lakartidningen
- Page 658 and 659: (1990): Broder S+, Am J Med 88, 31S
- Page 660 and 661: (1989): Valencia ME+, Rev Clin Esp
- Page 662 and 663: ZOLPIDEM Trade names: Ambien (Sanof
- Page 664 and 665: DRUGS RESPONSIBLE FOR COMMON REACTI
- Page 666 and 667: Ethambutol Ethanolamine Etoposide F
- Page 668 and 669: Procarbazine Progestins Promethazin
- Page 670 and 671: Erlotinib Ertapenem Escitalopram Et
- Page 672 and 673: Feverfew Floxuridine Fluconazole Fl
- Page 674 and 675: Insulin glulisine Interferon alfa I
- Page 676 and 677: Acamprosate Acebutolol Acetaminophe
- Page 678 and 679: Amobarbital Amoxicillin Amphoterici
- Page 680 and 681: Spironolactone Streptomycin Sulface
- Page 682 and 683: Miconazole Midazolam Minocycline Mi
- Page 684 and 685: Heroin Hydralazine Hydrochlorothiaz
- Page 686 and 687: Nefazodone Nevirapine Niacin Nicoti
- Page 688 and 689: Mephenytoin Mercaptopurine Mesalami
- Page 690 and 691: Cephradine Cetuximab Chamomile Chlo
568 VALRUBICIN<br />
VALRUBICIN<br />
Trade name: Valstar (Celltech)<br />
Indications: Bladder carcinoma<br />
Category: Antibiotic, anthracycline<br />
Half-life: N/A<br />
Clinically important, potentially hazardous interactions<br />
with: None<br />
Reactions<br />
Skin<br />
Irritation (sic) (2%)<br />
(2003): Irons BK+, Ann Pharmacother 37(7–8), 1024<br />
(2002): Biswas PN+, JHumHypertens16(11), 795<br />
(2000): de la Serna Higuera C, Med Clin (Barc) (Spanish)<br />
114, 599<br />
(1998): Frye Cb+, Pharmacotherapy 18, 866<br />
Bullous pemphigoid<br />
(2003): Femiano F, Minerva Stomatol 52(4), 187<br />
Eczema<br />
(2006): Selden ST, Chesapeake VA (from Internet) (observation)<br />
Edema (>1%)<br />
(2000): Prat H, Rev Med Chil (Spanish) 128, 475<br />
(1996): Corea L+, Clin Pharmacol Ther 60, 341<br />
Facial edema<br />
(2002): Biswas PN+, JHumHypertens16(11), 795<br />
Lupus erythematosus<br />
(2006): Sontheimer RD, Oklahoma City, OK (from Internet)<br />
(observation)<br />
Photosensitivity<br />
(1998): Frye Cb+, Pharmacotherapy (18) 866<br />
Pruritus (>2%)<br />
Psoriasis<br />
(2005): Litt JZ, Beachwood, OH (personal case) (observation)<br />
Rash (sic) (>2%)<br />
Urticaria<br />
(2000): de la Serna Higuera C, Med Clin (Barc) (Spanish)<br />
114, 599<br />
Mucosal<br />
Aphthous stomatitis (1–10%)<br />
Xerostomia (>10%)<br />
Nails<br />
Nails – onychocryptosis<br />
Nails – pigmentation<br />
Other<br />
Cough<br />
(2002): Biswas PN+, JHumHypertens16(11), 795<br />
(2000): Prat H, Rev Med Chil 128, 475<br />
Death<br />
(2001): Briggs GG+, Ann Pharmacother 35(7), 859<br />
Injection-site extravasation (
Change language